🇺🇸 FDA
Patent

US 12404313

GDNF fusion polypeptides and methods of use thereof

granted A61KA61K38/00A61P

Quick answer

US patent 12404313 (GDNF fusion polypeptides and methods of use thereof) held by Keros Therapeutics, Inc. expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Keros Therapeutics, Inc.
Grant date
Tue Sep 02 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K38/00, A61P, A61P25/00, A61P3/00